1H, 15N backbone assignment and comparative analysis of the wild type and G12C, G12D, G12V mutants of K-Ras bound to GDP at physiological pH

被引:0
|
作者
Gyula Pálfy
István Vida
András Perczel
机构
[1] Eötvös Loránd University,Laboratory of Structural Chemistry and Biology, Institute of Chemistry
[2] Eötvös Loránd University,MTA
来源
Biomolecular NMR Assignments | 2020年 / 14卷
关键词
Ras; G12C, G12D, G12V mutants; Cancer; NMR; Combined chemical shifts analysis;
D O I
暂无
中图分类号
学科分类号
摘要
K-Ras protein is a membrane-bound small GTPase acting as a molecular switch. It plays a key role in many signal transduction pathways regulating cell proliferation, differentiation, survival, etc. It alternates between its GTP-bound active and the GDP-bound inactive conformers regulated by guanine nucleotide exchange factors and GTPase activating proteins. Its most frequent oncogenic mutants are G12C, G12D, and G12V that have impaired GTPase activity, thus induce malignant tumors. Here we report the resonance assignment of the backbone 1H and 15N nuclei of K-Ras wildtype, G12C, G12D and G12V proteins’ catalytic G domain (1–169 residues) in GDP-bound state, and 13C of backbone and side chains of G12C mutant at physiological pH 7.4. Triple resonance data were used to get secondary structure information and backbone dynamics of G12C, the best-known drug target among K-Ras mutants. Simultaneous investigation of G12C, G12D and G12V mutants, along with the wild type form at the very same conditions allowed us to perform a comprehensive analysis based on the combined chemical shifts to reveal the effect of mutation at G12 position on structure. Intriguingly, the G12C and G12V mutants found to be structurally very similar at the three most important regions of K-Ras (P-loop, Switch-I, Switch-II), while the G12D mutant significantly differs at P-loop and Switch-II from the wildtype as well as G12C and G12V mutants. However, in Switch-I it hardly deviates from the wildtype protein.
引用
收藏
页码:1 / 7
页数:6
相关论文
共 45 条
  • [21] Immunogenicity of GI-4000 vaccine in adjuvant consolidation therapy following definitive treatment in patients with stage I-III adenocarcinoma of the lung with G12C, G12D, or G12V KRAS mutations
    D'Angelo, S. P.
    Park, B. J.
    Krug, L. M.
    Crevar, C.
    Medina, C. E.
    Sumner, D. K.
    Richman, J.
    Coeshott, C.
    Apelian, D.
    Cohn, A.
    Kris, M. G.
    Azzoli, C. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [22] Phase 2 Study of GI-4000 Vaccine as Adjuvant Consolidation Therapy Following Resection of Patients With Stage I-III Adenocarcinoma of the Lung With G12C, G12D, and G12V KRAS Mutations
    D'Angelo, S. P.
    Park, B.
    Krug, L.
    Crevar, C.
    Medina, C.
    Sumner, D.
    Richman, J.
    Cohn, A.
    Kris, M.
    Azzoli, C. G.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S504 - S504
  • [23] ALTA3263: an oral, KRAS isoform-selective, dual ON/OFF state, non-covalent inhibitor induces regressions across KRAS G12V, G12D, and G12C cancer models
    Wang, T.
    Ibanez, M.
    Yu, K.
    Fan, K.
    Juan, J.
    Perez, M.
    Smith, T.
    Walsh, B.
    Kang, V.
    Tyhonas, J.
    Alvarez, N.
    Tran, J.
    Moorefield, K. S.
    Phimister, A.
    Zhu, X.
    Chi, A.
    Bartberger, M. D.
    Murphy, E.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S5 - S6
  • [24] Phase II Study of the GI-4000 KRAS Vaccine After Curative Therapy in Patients With Stage I-III Lung Adenocarcinoma Harboring a KRAS G12C, G12D, or G12V Mutation
    Chaft, Jamie E.
    Litvak, Anya
    Arcila, Maria E.
    Patel, Payal
    D'Angelo, Sandra P.
    Krug, Lee M.
    Rusch, Valerie
    Mattson, Alicia
    Coeshott, Claire
    Park, Bernard
    Apelian, David M.
    Kris, Mark G.
    Azzoli, Christopher G.
    CLINICAL LUNG CANCER, 2014, 15 (06) : 405 - 410
  • [25] AMPLIFY-7P: Phase 1 and randomized phase 2 study of amphiphile immunotherapy ELI-002 7P as adjuvant treatment for subjects with G12D, G12R, G12V, G12C, G12A, G12S and G13D Kirsten rat sarcoma (KRAS)-mutated pancreatic ductal adenocarcinoma.
    Wainberg, Zev A.
    Chung, Vincent
    Devoe, Craig E.
    George, Thomas J.
    Welkowsky, Esther
    Kheoh, Thian
    Haqq, Christopher M.
    Pant, Shubham
    O'Reilly, Eileen Mary
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : TPS720 - TPS720
  • [26] Crystal Structure of a Human K-Ras G12D Mutant in Complex with GDP and the Cyclic Inhibitory Peptide KRpep-2d
    Sogabe, Satoshi
    Kamada, Yusuke
    Miwa, Masanori
    Niida, Ayumu
    Sameshima, Tomoya
    Kamaura, Masahiro
    Yonemori, Kazuko
    Sasaki, Shigekazu
    Sakamoto, Jun-ichi
    Sakamoto, Kotaro
    ACS MEDICINAL CHEMISTRY LETTERS, 2017, 8 (07): : 732 - 736
  • [27] In silico-guided sequence modifications of K-ras epitopes improve immunological outcome against G12V and G13D mutant KRAS antigens
    Ng, Allan Wee Ren
    Tan, Pei Jun
    Hoo, Winfrey Pui Yee
    Liew, Dek Shen
    Teo, Michelle Yee Mun
    Siak, Pui Yan
    Ng, Sze Man
    Tan, Ee Wern
    Rahim, Raha Abdul
    Lim, Renee Lay Hong
    Song, Adelene Ai Lian
    In, Lionel Lian Aun
    PEERJ, 2018, 6
  • [28] Retrospective comparative analysis of K-ras G12C vs other K-ras mutations in metastatic colorectal cancer patients treated with first-line chemotherapy doublet plus bevacizumab
    Giampieri, R.
    Lupi, A.
    Ziranu, P.
    Pecci, F.
    Pretta, A.
    Persano, M.
    Crocetti, S.
    Giglio, E.
    Bittoni, A.
    Mandolesi, A.
    Scartozzi, M.
    Berardi, R.
    ANNALS OF ONCOLOGY, 2021, 32 : S200 - S200
  • [29] Crystal structures of the state 1 conformations of the GTP-bound H-Ras protein and its oncogenic G12V and Q61L mutants
    Muraoka, Shin
    Shima, Fumi
    Araki, Mitsugu
    Inoue, Tomoko
    Yoshimoto, Akiko
    Ijiri, Yuichi
    Seki, Nobuaki
    Tamura, Atsuo
    Kumasaka, Takashi
    Yamamoto, Masaki
    Kataoka, Tohru
    FEBS LETTERS, 2012, 586 (12) : 1715 - 1718
  • [30] A phase 1 study of D3S-001, a second-generation GDP-bound KRAS G12C inhibitor, as monotherapy in patients with KRAS G12C-mutated solid tumors
    Cho, Byoung Chul
    Lu, Shun
    Lee, Myung Ah
    Song, Zhengbo
    Park, John
    Lim, Sun Min
    Li, Ziming
    Zhao, Jun
    Richardson, Gary
    Zhang, Yanqiao
    Zhang, Jun
    Liu, Anwen
    Chen, Cheng
    Wang, Jia
    Lu, Jingtao
    Rui, Haopeng
    Chen, Qian
    Wang, Hui
    Zhang, Jing
    Chen, Zhi Jian
    Mok, Tony
    CANCER RESEARCH, 2024, 84 (07)